Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Osteoporosis
How do you manage hepatotoxicity thought to be related to Romosozumab use?
Have you seen liver toxicity associated with Romosozumab?
Related Questions
Is it safe to combine Prolia with other immunosuppressants?
Is elevated bone specific alkaline phosphatase an absolute contraindication to teriparatide?
Are there any concerns with using denosumab in a patient with chronic hepatitis B infection on antiviral therapy?
What treatment options would you consider for a young patient with limited mobility, low bone mass and multiple vertebral compression fractures who is on dialysis for advanced kidney disease?
How should we interpret DXA scans in patients with Ankylosing Spondylitis who have ankylosis of the spine?
Is there a maximum duration for raloxifene use?
How do you manage pleuroparenchymal fibroelastosis in a patient with seronegative RA that is progressing on Rituxan and DMARD therapy?
Is it safe to continue azathioprine in a patient with severe bilateral panuveitis (thought to be related to sarcoidosis) and benign ethnic neutropenia, given worsening neutropenia since starting the medication, or should an alternative immunosuppressive agent be considered?
How do you approach a patient with elevated bone specific ALP (>2X the normal limit), but no other evidence of Paget's disease?
Would you use anabolic agents (romosozumab or PTH analogues) for osteoporosis treatment in patients with CKD?
